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Congenital Factor V (FV) deficiency is a rare bleeding disorder that inherit in 
autosomal recessive manner. Diagnosis of FV deficiency (FVD) is made by 
routine coagulation tests, FV activity and molecular analysis. In patients with 
FVD, routine coagulation tests including activated partial thromboplastin time 
(APTT), prothrombin time (PT), and even bleeding time (BT) are prolonged 
while thrombin time (TT) is normal. FV activity assay can use for 
confirmation of diagnosis as well as for differential diagnosis with acquired 
forms of disease. Mixing study can be used for screening of inhibitor against 
FV. In this situation, addition of normal plasma cannot correct prolonged PT 
and PTT while in congenital FVD prolongation is corrected. Molecular 
diagnosis of FVD is straight forward but due to large size of FV gene and 
genetic variability molecular diagnosis is restricted to research laboratory. 
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Introduction 
Blood Coagulation factor V (FV) known as a labile 
factor or proaccelarin  first discovered by Paul Owren 
in 1943 through a study on a woman that affected by 
hemophilia like syndrome. This protein has an 
essential role in hemostasis as it acts as a non-
enzymatic cofactor in prothrombinase complex. It has 
vital role in down regulation of factor VIII by 
increasing the effect of activated protein C .Therefore 
this coagulation factor has pro and anticoagulant 
activity 1).  
Factor V deficiency  
Congenital factor V (FV) deficiency is a rare 
hemorrhagic disorder with estimated incidence of 1 
per 1 million (1).  There are more than 200 patients 
with FVD were diagnosed up to now. Since disorder 
transmits in an autosomal recessive manner, 
distribution of disease in both sex is equal and higher 
frequency of disorder in any especial area was not 
reported but such other autosomal recessive disorders, 
areas with high rate of consanguineous marriage has a 
higher incidence of disorder (2, 3). FV has a gene 
with 74 kb length on long arm of chromosome 1 and 
more than 100 different disease-causing mutations 
such as nonsense, frame shift, missense, and splice-
site mutations were observed throughout the gene. 
Moreover, approximately 900 polymorphisms were 
described in FV gene (1, 3). Based on residual FV 
activity in plasma, FVD divided into three groups of 
severe with undetectable FV activity, moderate with 
less than 10% activity and finally, mild FVD with 
10% or more than 10% FV activity. No direct 
correlation was observed between factor activity and 
severity of bleeding episodes in patients with FVD  
(4). A wide spectrum of clinical presentations was 
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observed in patients with FVD. This bleeding 
episodes can be as mild as recurrent epistaxis or can 
be a life threatening bleeding diathesis such as central 
nervous system (CNS) bleeding but this kind of 
bleedings are less common in FVD and are more 
common in patients  with other rare bleeding disorder  
especially factor XIII deficiency (5, 6). Diagnosis of 
FVD can be made based on routine coagulation tests 
including activated partial thromboplastin time 
(APTT), Prothrombin time (PT) as well as more 
specific assay such as FV activity and antigen assays 
and finally by molecular analysis and determination 
of FVD underline mutation. Therefore, in this study, 
we presented different required tests for diagnosis of 
FVD including routine coagulation tests, FV antigen 
and activity assays as well as FV inhibitor detection 
and assay and molecular diagnosis of FVD (7). 
Diagnosis of factor V 
deficiency 
A set of clinical presentations, family history 
and laboratory assessment is useful for diagnosis of 
FVD. Patient with continues bleeding suspected to 
FVD is examined by routine coagulation tests 
including Bleeding Time (BT), Thrombin Time (TT) 
Prothrombin Time (PT), Activated Partial 
Thromboplastin Time (APTT), and platelet count(1, 
3). Since FV is a part of common pathway, a patient 
with FVD has a normal TT and platelet count but a 
prolonged APTT and PT. This situation should be 
distinguished from acquired form of disease that are 
result from inhibitor development against coagulation 
FV or acquired form due to liver diseases. In severe 
FVD, BT can increase (4, 7). Combined deficiency of 
factor V-VIII always should be in mind to distinguish 
from isolated FVD. With complementary tests, all of 
these situations can be distinguished from FVD (7). 
Screening test for present of inhibitor can rule out this 
phenomenon. Liver function tests (LFT) with 
appropriate additional assessments can determine 
patients liver situation. FVIII coagulant activity 
should always be measured in all suspected patients to 
FVD in order to exclude the combined deficiency of 
FV and factor VIII (FVIII). In combined FV and 
FVIII deficiency low levels of both factors (usually 
5–20%) is observed (7, 8). Moreover, in patients with 
combined FV and FVIII deficiency PT and PTT is 
mild to moderately be increased.  
Molecular analysis and determination of 
underline mutation in FV gene is straight forward but 
because a wide spectrum of mutation was observed in 
patients with FVD, molecular diagnosis is not applied 
in clinical laboratories (8, 9). 
Table 1: Results of coagulation tests in patients with factor V deficiency. 
 
Test Patient  Normal Value 
Bleeding Time (BT) (template) 
(min) 
5-20 10> 
Thrombin Time (TT) (sec) 10-16 10-16 
Prothrombin Time (PT) (sec) 40-50 10-13 
Activated Partial Thromboplastin 
Time (APTT) (sec) 
50-60 28-35 
Factor V activity (%)Mild 10 ≤  70-150 
Moderate < 10  
Severe Undetectable level  
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Routine coagulation tests in 
factor V deficiency 
At the baseline, each patient with continues 
bleeding can be screened by routine coagulation tests. 
Among these routine tests, PT and PTT were more 
important for coagulation factor deficiency and 
different coagulation factor deficiency can lead to 
prolongation of one or both of these tests. 
Prolongation of each of these tests can be further 
followed by more specific tests to determined 
underlined factor deficiency (10). 
Prolonged aPTT test is observed in the 
deficiency of factors that belong to common (X, V, II 
and fibrinogen) and intrinsic (XI, IX and VIII) 
pathways of coagulation cascade as well as during 
medication by heparin. PT test evaluates the 
coagulation factors involved in the extrinsic (factor 
VII) and common (factors X, V, II and fibrinogen) 
pathways of coagulation cascade, and is also used for 
monitoring of warfarin therapy both of PT and PTT 
are prolong in patients with FVD but simultaneous 
prolongation of these tests can be observed in 
deficiency of each factor in common pathway (factors 
X, V, II, I) (7, 8, 11). In this situation, addition of 
normal plasma to patient’s plasma can correct 
prolonged PT and PTT. In FVD, if normal plasma 
that was absorbed by aluminum hydroxide or barium 
salts is added to patient’s plasma and PT was 
corrected diagnosis of FVD is suspected. Another 
interesting finding in FVD is prolongation of BT. 
Precise, cause of this prolonged BT is not clear but it 
can attribute to platelet FV (7). Approximately 20% 
of plasma FV is absorbed in platelet α granules. This 
platelet FV is a site for activated Factor X (FXa) but 
the precise mechanism of this prolonged BT with 
platelet FV is not clear. Inhibitor development is a 
rare phenomenon in patients with FVD or extremely 
rare in healthy individuals. This inhibitor against FV 
led to prolongation of both PT and PTT (7, 8). In 
contrast to FVD that prolonged PT and PTT was 
corrected by addition of normal plasma, in cases with 
inhibitor against FV, This is not corrected in similar 
situation. It’s worth noting, that inhibitor against FV 
in congenital FVD is IgG that similar to inhibitor 
against factor VIII is time dependent (12). 
Factor V activity and antigen 
assays 
In a suspected patient to FVD with a prolonged 
PT and PTT next step is performing a FV activity 
assay. Based on factor activity, patients with FVD is 
divided to severe (with undetectable level of factor 
V), moderate (<10%) and mild (10≤) forms. Several 
methods including manual and automated methods 
were described that each of them has their own 
advantages and disadvantages (7, 8).  
If a patient suspected to FVD with prolonged 
PT and PTT, next step to achieve a definitive 
diagnosis of the disease is to perform a FV activity 
(7).  
FV specific PT assays using known FV 
deficient plasma can confirm the deficiency and 
determine the approximate functional factor levels. 
FV antigen levels (FV: Ag) can be determined by 
ELISA method. In type I of FVD, both FV activity 
and antigen are decreased but in type II FV activity is 
decreased but antigen, level is normal or near the 
normal (4, 7). 
Molecular diagnosis of factor 
V deficiency 
FV protein is encoded by large gene with 74kb 
length on large arm of chromosome 1 (1q24.2). More 
than 100 different mutations were observed in 
patients with FVD. A variety of gene defects 
including nonsense and missense mutations, 
insertions, deletions, and splice-site mutations were 
observed in patients with FVD (13). About 50% of 
mutations were missense and a large number of 
nonsense mutations. These different mutations were 
scattered throughout the FV gene without any 
recurrent gene defect that can be used for diagnosis of 
FVD. Since FV gene is large and complex with 25 
exons, and diversity of FV gene defects, molecular 
diagnosis of FVD is not entered in clinical laboratory 
and is restricted to research laboratory (9, 11). 
Conclusion 
Taking all aforementioned in to account 
it can be concluded that diagnosis of FV 
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deficiency was done by routine coagulation 
laboratory tests and confirmed by measurement 
of factor activity. In addition molecular basis 
can be helpful in diagnosis of disorder. 
Determination of underline mutation allocated 
to each region around world can be used as a 
complementary test in diagnosis and also can 
be vital in prenatal diagnosis and preventing of 
distribution of disease. 
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